These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 15611505)

  • 41. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
    Warnecke-Eberz U; Hokita S; Xi H; Higashi H; Baldus SE; Metzger R; Brabender J; Bollschweiler E; Mueller RP; Dienes HP; Hoelscher AH; Schneider PM
    Oncol Rep; 2005 Jun; 13(6):1241-6. PubMed ID: 15870949
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer.
    Santos AM; Sousa H; Portela C; Pereira D; Pinto D; Catarino R; Rodrigues C; Araújo AP; Lopes C; Medeiros R
    Biochem Biophys Res Commun; 2006 Feb; 340(1):256-62. PubMed ID: 16364249
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preoperative chemoradiotherapy for rectal cancer: randomized trial comparing oral uracil and tegafur and oral leucovorin vs. intravenous 5-fluorouracil and leucovorin.
    de la Torre A; García-Berrocal MI; Arias F; Mariño A; Valcárcel F; Magallón R; Regueiro CA; Romero J; Zapata I; de la Fuente C; Fernández-Lizarbe E; Vergara G; Belinchón B; Veiras M; Molerón R; Millán I
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):102-10. PubMed ID: 17869446
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Functional p53 status as a biomarker for chemotherapy response in oral-cavity cancer.
    Mroz EA; Rocco JW
    J Clin Oncol; 2010 Feb; 28(5):715-7. PubMed ID: 20048171
    [No Abstract]   [Full Text] [Related]  

  • 45. Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
    Novarino A; Satolli MA; Chiappino I; Giacobino A; Bellone G; Rahimi F; Milanesi E; Bertetto O; Ciuffreda L
    Am J Clin Oncol; 2009 Feb; 32(1):44-8. PubMed ID: 19194124
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.
    Ajani JA; Winter K; Okawara GS; Donohue JH; Pisters PW; Crane CH; Greskovich JF; Anne PR; Bradley JD; Willett C; Rich TA
    J Clin Oncol; 2006 Aug; 24(24):3953-8. PubMed ID: 16921048
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma.
    Abbrederis K; Bassermann F; Schuhmacher C; Voelter V; Busch R; Roethling N; Sendler A; Siewert JR; Peschel C; Lordick F
    Ann Thorac Surg; 2006 Jul; 82(1):293-7. PubMed ID: 16798232
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: a new treatment paradigm.
    Urba S; Wolf G; Eisbruch A; Worden F; Lee J; Bradford C; Teknos T; Chepeha D; Prince M; Hogikyan N; Taylor J
    J Clin Oncol; 2006 Feb; 24(4):593-8. PubMed ID: 16380415
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus.
    Javeri H; Arora R; Correa AM; Hofstetter WL; Lee JH; Liao Z; McAleer MF; Maru D; Bhutani MS; Swisher SG; Izzo JG; Ajani JA
    Cancer; 2008 Sep; 113(6):1302-8. PubMed ID: 18623381
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.
    Hitt R; Ciruelos E; Amador ML; Benito A; Sanchez JJ; Ballestin C; Cortes-Funes H
    Eur J Cancer; 2005 Feb; 41(3):453-60. PubMed ID: 15691646
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adjuvant chemotherapy with cisplatin, etoposide, fluorouracil and leucovorin for gastric carcinoma.
    Papadakou M; Xydakis E; Bonios M; Makropoulou E; Boukis C; Kakavoulis T; Karaliotas C; Panagos G
    J BUON; 2006; 11(3):285-9. PubMed ID: 17309151
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
    Xi H; Baldus SE; Warnecke-Eberz U; Brabender J; Neiss S; Metzger R; Ling FC; Dienes HP; Bollschweiler E; Moenig S; Mueller RP; Hoelscher AH; Schneider PM
    Clin Cancer Res; 2005 Dec; 11(23):8341-7. PubMed ID: 16322294
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
    Haller DG; Catalano PJ; Macdonald JS; O'Rourke MA; Frontiera MS; Jackson DV; Mayer RJ
    J Clin Oncol; 2005 Dec; 23(34):8671-8. PubMed ID: 16314627
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
    Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
    J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Significance of biological markers for predicting prognosis and selecting chemotherapy regimens of advanced gastric cancer patients between continuous infusion of 5-FU and a combination of 5-FU and cisplatin.
    Boku N; Ohtsu A; Yoshida S; Shirao K; Shimada Y; Hyodo I; Saito H; Miyata Y;
    Jpn J Clin Oncol; 2007 Apr; 37(4):275-81. PubMed ID: 17522103
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: gene expression analysis with pathologic validation.
    Jhawer M; Coit D; Brennan M; Qin LX; Gonen M; Klimstra D; Tang L; Kelsen DP; Shah MA
    Am J Clin Oncol; 2009 Aug; 32(4):356-62. PubMed ID: 19381079
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Primary non-Hodgkin's lymphoma of the paranasal sinuses: a report of 14 cases].
    Su ZY; Zhang DS; Zhu MQ; Shi YX; Jiang WQ
    Ai Zheng; 2007 Aug; 26(8):919-22. PubMed ID: 17697560
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer.
    Licitra L; Locati LD; Cavina R; Garassino I; Mattavelli F; Pizzi N; Quattrone P; Valagussa P; Gianni L; Bonadonna G; Solero CL; Cantu G
    Ann Oncol; 2003 Mar; 14(3):367-72. PubMed ID: 12598339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.